Premium
Ovarian Cancer: Evaluation of the Leukocyte Adherence Inhibition Assay
Author(s) -
Hicks. Leanne J.,
Dodd. Janis K.,
Tyler John P. P.,
Hudson C. N.
Publication year - 1984
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1984.tb00723.x
Subject(s) - ovarian cancer , medicine , cancer , oncology , disease , cancer antigen , immunology , gastroenterology
The Leukocyte Adherence Inhibition (LAI) assay has been evaluated for clinical use in the management of patients with ovarian cancer. Studies on the tube method included determination of the optimal concentration of cells used and the type, or presence or absence, of serum supplement utilised; also the effect on LAI of various specific and non‐specific crude antigen preparations. A refined assay was used to compare data from 21 patients with epithelial ovarian cancer, a miscellaneous group of other types of cancer and control groups of healthy pregnant and non‐pregnant women of reproductive age. Positive LAI responses were produced in some patients with ovarian cancer, but there were no significant differences between the groups. It was concluded that lack of reactivity in patients with widespread disease, early loss of reactivity in remission, and moderation of the LAI index by concurrent therapy would limit the practical use of this assay to monitor the host response of patients with ovarian cancer.